Safety

Who Should Not Take GLP-1 Medications: Contraindications & Precautions

GLP-1 Companion · 8 min read

GLP-1 receptor agonists — including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — have transformed obesity and diabetes treatment. However, like all potent medications, they carry specific contraindications and precautions. Understanding who should not take these drugs, and who needs extra monitoring, is essential for safe use.

Absolute Contraindications: Who Must Not Take GLP-1 Medications

Absolute contraindications are conditions in which the risk of serious harm is so high that the medication should never be used. For GLP-1 receptor agonists, four absolute contraindications exist.

1. Personal or Family History of Medullary Thyroid Carcinoma (MTC)

All GLP-1 receptor agonists carry a black box warning regarding medullary thyroid carcinoma, a rare cancer of the thyroid C-cells (parafollicular cells). GLP-1 receptors are expressed on thyroid C-cells, and rodent studies showed dose-dependent C-cell hyperplasia and MTC. Anyone with a personal history of MTC or a first-degree family member with MTC must not use these medications. The concern applies to the entire drug class.

2. Multiple Endocrine Neoplasia Syndrome Type 2 (MEN2)

MEN2 is a hereditary syndrome predisposing patients to MTC, pheochromocytoma, and parathyroid disease. Because MTC is a defining feature of MEN2, the same MTC-related boxed warning applies. Both MEN2A and MEN2B are absolute contraindications.

3. Pregnancy

GLP-1 medications should not be used during pregnancy. Animal studies have demonstrated embryo-fetal toxicity at clinically relevant exposures. Current guidelines recommend discontinuing GLP-1 medications at least 2 months before attempting to conceive, allowing the drug to clear given its long half-life. Women who become pregnant while on a GLP-1 medication should stop immediately and inform their obstetric care team.

4. Known Serious Hypersensitivity to Semaglutide or Tirzepatide

A prior serious allergic reaction — including anaphylaxis, angioedema, or severe urticaria — to any component of these medications is an absolute contraindication. Patients with a hypersensitivity history to one GLP-1 agent should discuss with their allergist and prescriber before trying another agent in the class, as cross-reactivity is possible.

Strong Relative Contraindications: Discuss Carefully With Your Provider

Relative contraindications are conditions where GLP-1 medications may still be used in selected patients after careful risk-benefit discussion, but where increased caution, closer monitoring, or avoidance is often recommended.

• Personal history of pancreatitis: GLP-1 medications carry a precautionary warning about pancreatitis. While large clinical trials have not confirmed a causal link, patients with prior acute or chronic pancreatitis are often excluded from treatment. A history of severe or recurrent pancreatitis is generally considered a reason to avoid these drugs. Milder, isolated episodes may be assessed individually.
• Active gallbladder disease or prior cholecystectomy with ongoing symptoms: GLP-1 medications increase the risk of gallstone formation (primarily through rapid weight loss). Patients with active cholecystitis, symptomatic cholelithiasis, or ongoing biliary symptoms post-cholecystectomy warrant careful evaluation before starting.
• Severe gastroparesis: GLP-1 medications slow gastric emptying as part of their mechanism of action. In patients with pre-existing gastroparesis — particularly diabetic gastroparesis — this slowing effect can significantly worsen symptoms, including nausea, vomiting, early satiety, and gastric bezoar formation. Severe gastroparesis is a reason to avoid these medications.
• Inflammatory bowel disease (active Crohn's disease or ulcerative colitis): Data in patients with active IBD is very limited. The GI side effects of GLP-1 medications (nausea, diarrhea, abdominal pain) can be difficult to distinguish from IBD flares, potentially complicating disease management. Patients with active disease should use caution and discuss this with their gastroenterologist.
• Eating disorders — particularly anorexia nervosa: GLP-1 medications significantly suppress appetite and food intake. In patients with restrictive eating disorders, this pharmacological suppression of appetite could exacerbate harmful restriction. These medications are generally not recommended in patients with active anorexia nervosa.
• Severe hepatic impairment: Limited pharmacokinetic data exists for patients with severe liver disease (Child-Pugh Class C). No dose adjustment is specified, but caution and monitoring are warranted given uncertain drug behavior in this population.

Drug Interactions Requiring Attention Before Starting

GLP-1 medications interact with several common drug classes, primarily through two mechanisms: altered glucose homeostasis and slowed gastric emptying affecting oral drug absorption.

1. Insulin and sulfonylureas: The combination of a GLP-1 agent with insulin or a sulfonylurea (such as glipizide, glimepiride, or glyburide) substantially increases the risk of hypoglycemia. Insulin doses often need to be reduced by 20-50% when starting a GLP-1 medication. Sulfonylurea doses are frequently reduced by 50% or discontinued. Glucose monitoring is essential during dose transitions.
2. Oral medications with narrow therapeutic windows: Because GLP-1 medications slow gastric emptying, oral medications that rely on rapid or predictable gastric absorption may have altered timing and peak levels. Warfarin (Coumadin) is a key example — INR should be monitored more frequently after starting a GLP-1. Thyroid hormone replacements (levothyroxine) are similarly affected; TSH should be rechecked 6-8 weeks after starting. Some antibiotics with narrow windows (certain macrolides, fluoroquinolones) also warrant attention.
3. Oral contraceptives: GLP-1 medications can reduce the peak concentration (Cmax) of oral contraceptives by delaying gastric absorption. Backup contraception (such as condoms) is recommended for at least 4 weeks after starting a GLP-1 medication. This is particularly relevant given that stopping GLP-1 therapy is recommended at least 2 months before attempting pregnancy.

Recommended Baseline Monitoring Before Starting

Before initiating GLP-1 therapy, a standard baseline workup helps identify contraindications, establish reference values, and ensure safe prescribing. Typical pre-treatment labs and assessments include:

• HbA1c: To assess glycemic control and confirm diabetes status (or rule it out in weight-loss-only candidates)
• Fasting lipid panel: Baseline cardiovascular risk assessment; GLP-1 medications modestly improve lipid profiles
• Kidney function: eGFR and serum creatinine — GLP-1 medications are generally safe in chronic kidney disease, but this establishes a baseline and identifies severe impairment (eGFR <15)
• Liver enzymes (ALT, AST): Identifies hepatic impairment; fatty liver disease is common in this population
• Thyroid function (TSH): Establishes baseline; identifies pre-existing thyroid conditions; important if levothyroxine is being taken
• Complete blood count (CBC): General baseline; anemia can cause fatigue that overlaps with GLP-1 side effects

Special Populations With Limited Data

Several populations were largely excluded from major GLP-1 clinical trials, leaving limited safety and efficacy data:

• Heart failure (NYHA Class IV): Most cardiovascular outcomes trials excluded patients with severe heart failure. The SELECT trial enrolled patients with established cardiovascular disease but excluded NYHA Class IV. Caution and cardiology consultation are appropriate.
• Severe renal impairment (eGFR <15 or on dialysis): Semaglutide is primarily eliminated via proteolytic degradation rather than renal excretion, so renal impairment does not require dose adjustment. However, GI fluid losses from nausea and vomiting can worsen renal function in patients with limited reserve. Close monitoring is warranted.
• Solid organ transplant recipients on immunosuppressants: This population is excluded from most trials. The primary concern is drug interaction — GLP-1 slowing of gastric absorption could affect the timing and levels of critical immunosuppressants like tacrolimus or cyclosporine, which have narrow therapeutic windows. Transplant teams should be involved in prescribing decisions.

The decision to start a GLP-1 medication should always be individualized. A strong contraindication is not a negotiating point — but for relative contraindications and special populations, thoughtful shared decision-making between patient and provider can often identify a safe path forward.

Summary: Key Questions to Review With Your Provider

Before starting a GLP-1 medication, consider discussing these questions with your healthcare provider:

1. Do I or any first-degree relatives have a history of medullary thyroid carcinoma or MEN2?
2. Have I ever had pancreatitis, and how severe was it?
3. Do I have active gallbladder disease or gastroparesis?
4. Am I pregnant, planning to become pregnant, or using oral contraceptives?
5. What medications do I take that have narrow therapeutic windows or require precise absorption timing?
6. Do I take insulin or sulfonylureas that may need dose adjustment?
7. Are there any baseline lab values I should have checked before starting?

GLP-1 medications are highly effective and broadly safe for most patients. Identifying the minority of patients who should avoid them — or who require extra monitoring — is what makes that safety record possible.

Sources

• Ozempic (semaglutide) Prescribing Information. Novo Nordisk.
• Mounjaro (tirzepatide) Prescribing Information. Eli Lilly.